Loading
Pucotenlimab is Lepu Biopharma's PD-1 antibody, approved in China in 2022 for mismatch-repair-deficient solid tumours and for melanoma, and in a phase 3 trial in colorectal cancer.
Taizhou Hanzhong (Lepu Biopharma) developed pucotenlimab (HX008), approved by the NMPA in July 2022 for previously treated MSI-high or mismatch-repair-deficient advanced solid tumours, China's first tissue-agnostic PD-1 approval, and for unresectable or metastatic melanoma after prior therapy. A phase 3 trial in metastatic colorectal cancer is registered.
Blocks PD-1 on T cells so tumour cells cannot switch them off through PD-L1. Connects to PD-1.
1.Pucotenlimab binds PD-1.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| CN | 2022 | Previously treated MSI-high or dMMR advanced solid tumours; unresectable or metastatic melanoma after prior therapy |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Pucotenlimab" OR ABSTRACT:"Pucotenlimab" OR TITLE:"HX008" OR ABSTRACT:"HX008") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Pucotenlimab, not a curated reading list.
Shares A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcin, Lepu Biopharma and the tag pipeline.
Shares Lepu Biopharma and the tag pipeline.
Shares Lepu Biopharma and the tag pipeline.
Shares Lepu Biopharma and the tag pipeline.
Shares PD-1, Melanoma, Colorectal cancer and the tag pipeline.
Shares Melanoma, Colorectal cancer and the tag pipeline.
Shares Colorectal cancer, Immune checkpoint inhibitors and the tag pipeline.